LungLife AI - Block Listing Application

November 22, 2021

10 November 2021

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Application

 

LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the “Block Admission”) has been made to the London Stock Exchange for up to 1,356,139 common shares of US $0.0001 each (the “Block Listing Shares”) to be admitted to trading on AIM (“Admission”).

 

The common shares that are being reserved under this block listing application will be issued by the Company, as required, in order to satisfy the exercise of share options and vested awards pursuant to the terms of the following share plans (the “Schemes”):

 

Scheme No. of common shares under
block listing application
2010 Stock Incentive Plan 480,775
2020 Stock Incentive Plan 201,374
2021 Omnibus Long-Term Incentive Plan 673,990

 

The Block Listing Shares will, upon issue, rank equally with all other common shares of US $0.0001 each in the capital of the Company that are then in issue. The Block Listing Admission is expected to become effective on 15 November 2021.

 

For the full announcement, please click here.

Subscribe for Email Alerts

This field is for validation purposes and should be left unchanged.
© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
magnifiercrossmenuchevron-down